{"uri": "eng-9419039", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Coronavirus", "type": "wiki", "score": 100, "label": {"eng": "Coronavirus"}}, {"uri": "http://en.wikipedia.org/wiki/Monoclonal_antibody", "type": "wiki", "score": 94, "label": {"eng": "Monoclonal antibody"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_trial", "type": "wiki", "score": 94, "label": {"eng": "Clinical trial"}}, {"uri": "http://en.wikipedia.org/wiki/Pre-exposure_prophylaxis", "type": "wiki", "score": 91, "label": {"eng": "Pre-exposure prophylaxis"}}, {"uri": "http://en.wikipedia.org/wiki/Infection", "type": "wiki", "score": 91, "label": {"eng": "Infection"}}, {"uri": "http://en.wikipedia.org/wiki/Titer", "type": "wiki", "score": 88, "label": {"eng": "Titer"}}, {"uri": "http://en.wikipedia.org/wiki/Efficacy", "type": "wiki", "score": 85, "label": {"eng": "Efficacy"}}, {"uri": "http://en.wikipedia.org/wiki/Vaccination", "type": "wiki", "score": 85, "label": {"eng": "Vaccination"}}, {"uri": "http://en.wikipedia.org/wiki/Virus", "type": "wiki", "score": 85, "label": {"eng": "Virus"}}, {"uri": "http://en.wikipedia.org/wiki/Cohort_study", "type": "wiki", "score": 72, "label": {"eng": "Cohort study"}}, {"uri": "http://en.wikipedia.org/wiki/Biopharmaceutical", "type": "wiki", "score": 71, "label": {"eng": "Biopharmaceutical"}}, {"uri": "http://en.wikipedia.org/wiki/Immunodeficiency", "type": "wiki", "score": 69, "label": {"eng": "Immunodeficiency"}}, {"uri": "http://en.wikipedia.org/wiki/Neutralizing_antibody", "type": "wiki", "score": 68, "label": {"eng": "Neutralizing antibody"}}, {"uri": "http://en.wikipedia.org/wiki/Serum_(blood)", "type": "wiki", "score": 64, "label": {"eng": "Serum (blood)"}}, {"uri": "http://en.wikipedia.org/wiki/Immunity_(medical)", "type": "wiki", "score": 57, "label": {"eng": "Immunity (medical)"}}, {"uri": "http://en.wikipedia.org/wiki/SARS-CoV-2", "type": "wiki", "score": 56, "label": {"eng": "SARS-CoV-2"}}, {"uri": "http://en.wikipedia.org/wiki/Nasdaq", "type": "wiki", "score": 51, "label": {"eng": "Nasdaq"}}, {"uri": "http://en.wikipedia.org/wiki/Intravenous_therapy", "type": "wiki", "score": 49, "label": {"eng": "Intravenous therapy"}}, {"uri": "http://en.wikipedia.org/wiki/Vaccine", "type": "wiki", "score": 48, "label": {"eng": "Vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Placebo-controlled_study", "type": "wiki", "score": 46, "label": {"eng": "Placebo-controlled study"}}], "eventDate": "2024-03-22", "totalArticleCount": 6, "title": {"eng": "Invivyd reports interim COVID-19 antibody trial data By Investing.com"}, "summary": {"eng": "WALTHAM, Mass. - Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company, announced interim exploratory data from its Phase 3 CANOPY clinical trial regarding VYD222, an investigational monoclonal antibody for COVID-19 pre-exposure prophylaxis.\n\nThe trial aims to understand the relationship between serum virus neutralizing antibody (sVNA) titers and clinical efficacy, particularly in individuals with prior immunity from vaccination or infection.\n\nThe company shared an update on symptomatic COVID-"}, "location": null, "categories": [{"uri": "dmoz/Health/Conditions_and_Diseases/Infectious_Diseases", "label": "dmoz/Health/Conditions and Diseases/Infectious Diseases", "wgt": 100}, {"uri": "dmoz/Health/Conditions_and_Diseases/Immune_Disorders", "label": "dmoz/Health/Conditions and Diseases/Immune Disorders", "wgt": 100}, {"uri": "dmoz/Health/Child_Health/Immunizations", "label": "dmoz/Health/Child Health/Immunizations", "wgt": 100}, {"uri": "news/Business", "label": "news/Business", "wgt": 76}], "articleCounts": {"eng": 6}, "sentiment": 0.1450980392156862, "wgt": 448761600, "relevance": 1}